Litcius/Paper detail

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

Noam Barda, Yaniv Lustig, Victoria Indenbaum, Daniel Zibly, Gili Joseph, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Limor Kliker, Bayan Abd Elkader, Eytan Ben‐Ami, Michal Canetti, Ravit Koren, Shiri Katz-Likvornik, Osnat Halpern, Ella Mendelson, Ram Doolman, Dror Harats, Yitshak Kreiss, Michal Mandelboim, Gili Regev‐Yochay

2023Clinical Microbiology and Infection15 citationsDOIOpen Access PDF

Topics & Concepts

TiterImmunogenicityVaccinationNeutralizationMedicineVirologyBivalent (engine)Neutralizing antibodyAntibodyImmunologyChemistryOrganic chemistryMetalSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up | Litcius